Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31419342 | 0.92 | NPC1 (0.53) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL27600818 | 0.87 | NPC1 (0.56) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL21355583 | 0.86 | NPC1 (0.55) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL31435495 | 0.85 | HTT (0.61) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL13597529 | 0.85 | HTT (0.61) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL27668254 | 0.82 | NPC1 (0.52) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL31419331 | 0.82 | MAOB (0.55) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL21355246 | 0.81 | NPC1 (0.51) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL29793278 | 0.81 | MAOB (0.56) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL26680685 | 0.81 | MAOB (0.56) | NPC1RAB9AALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021066922-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-7629468-B2 | Neuroprotectants, analgesics or anticonvulsants | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-08 | — | — | US | disclosed |
| US-7517517-B2 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| EP-1332133-B1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| US-7115630-B2 | Metabotropic glutamate receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-03 | — | — | US | disclosed |
| US-20060083676-A1 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTIA N.V. (BE) | 2006-04-20 | — | — | US | disclosed |
| CN-1703403-A | Metabotropic glutamate receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-30 | — | — | CN | disclosed |
| US-20050209273-A1 | Metabotropic glutamate receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-22 | — | — | US | disclosed |
| EP-1492571-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040082592-A1 | Metabotropic glutamate receptor antagonists | JANSSEN-CILAG SA (FR) | 2004-04-29 | — | — | US | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
| EP-1332133-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002028837-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082592-A1 | Metabotropic glutamate receptor antagonists | GRM3, GRM1, GRIN3A | NPC1 1760/4885RAB9A 4375/4885ALDH1A1 1904/4885 |
| US-20060083676-A1 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | GRM3, GRM1, GRM2 | NPC1 2238/4885RAB9A 3337/4885ALDH1A1 2136/4885 |
| US-20050209273-A1 | Metabotropic glutamate receptor antagonists | GRM3, GRM1, GRIN3A | NPC1 1628/4885RAB9A 4158/4885ALDH1A1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.